Awareness of anti-malarial policy and malaria treatment practices of patent medicine vendors in three Nigerian states.

O. Oladepo, William R Brieger, B. Adeoye, B. Lawal, David Peters

Research output: Contribution to journalArticle

Abstract

This paper assesses Patent Medicine Vendors' (PMVs) practices, awareness of new Nigerian Artemisinin Combination Therapy (ACT) policy, the anti-malarial drugs in stock and how the PMVs identify fake drugs. PMVs and medicine shops were selected through a multi-stage random sampling process, beginning with the purposive selection of three states that reflect major geographic and ethnolinguistic areas of Nigeria: Oyo (Southwest-Yoruba), Kaduna (Northcentral-Hausa), and Enugu (Southeast-Igbo). Local Government Areas (LGAs) in selected states were stratified into urban and rural strata, with two LGAs randomly sampled from each stratum in each state, and one ward (urban LGAs) or community (rural LGAs) randomly sampled from a list in each LGA. A complete listing of PMVs and drug shops was constructed at each site, yielding 111 PMVs and 106 medicine shops. Out of this number, a total of 110 PMVs consented to be interviewed. Some PMVs (43.1%) were aware of the 2005 government policy that changed the recommended first-line treatment for malaria from chloroquine (CQ) to ACT, but significant differences were found between states (p <0.001). PMV shops stocked many brands of anti-malarial drugs (average 5.5 brands), with ACTs stocked in only 8.5% of the stores at a mean price of N504 ($4) per treatment, compared to sulfadoxine-pyrimethamine (92% of shops, mean price of N90 ($0.7) and even monotherapy artesunates (32% of shops, mean price of N39 ($0.3). The PMVs identify a drug not bearing the National Agency for Food & Drug Administration and Control (NAFDAC) identification number as being fake or counterfeit. PMVs need to be a part of the strategy to change treatment to ACTs if there are to be meaningful changes in the anti-malarial drugs that Nigerians receive.

Original languageEnglish (US)
Pages (from-to)345-352
Number of pages8
JournalAfrican Journal of Medicine and Medical Sciences
Volume40
Issue number4
StatePublished - Dec 2011
Externally publishedYes

Fingerprint

Nonprescription Drugs
Antimalarials
Malaria
Local Government
Pharmaceutical Preparations
Counterfeit Drugs
Medicine
Drug and Narcotic Control
Chloroquine
Rural Population
Nigeria

ASJC Scopus subject areas

  • Medicine(all)

Cite this

@article{6e7898f000eb4af7b43fb5c9e7d86c9e,
title = "Awareness of anti-malarial policy and malaria treatment practices of patent medicine vendors in three Nigerian states.",
abstract = "This paper assesses Patent Medicine Vendors' (PMVs) practices, awareness of new Nigerian Artemisinin Combination Therapy (ACT) policy, the anti-malarial drugs in stock and how the PMVs identify fake drugs. PMVs and medicine shops were selected through a multi-stage random sampling process, beginning with the purposive selection of three states that reflect major geographic and ethnolinguistic areas of Nigeria: Oyo (Southwest-Yoruba), Kaduna (Northcentral-Hausa), and Enugu (Southeast-Igbo). Local Government Areas (LGAs) in selected states were stratified into urban and rural strata, with two LGAs randomly sampled from each stratum in each state, and one ward (urban LGAs) or community (rural LGAs) randomly sampled from a list in each LGA. A complete listing of PMVs and drug shops was constructed at each site, yielding 111 PMVs and 106 medicine shops. Out of this number, a total of 110 PMVs consented to be interviewed. Some PMVs (43.1{\%}) were aware of the 2005 government policy that changed the recommended first-line treatment for malaria from chloroquine (CQ) to ACT, but significant differences were found between states (p <0.001). PMV shops stocked many brands of anti-malarial drugs (average 5.5 brands), with ACTs stocked in only 8.5{\%} of the stores at a mean price of N504 ($4) per treatment, compared to sulfadoxine-pyrimethamine (92{\%} of shops, mean price of N90 ($0.7) and even monotherapy artesunates (32{\%} of shops, mean price of N39 ($0.3). The PMVs identify a drug not bearing the National Agency for Food & Drug Administration and Control (NAFDAC) identification number as being fake or counterfeit. PMVs need to be a part of the strategy to change treatment to ACTs if there are to be meaningful changes in the anti-malarial drugs that Nigerians receive.",
author = "O. Oladepo and Brieger, {William R} and B. Adeoye and B. Lawal and David Peters",
year = "2011",
month = "12",
language = "English (US)",
volume = "40",
pages = "345--352",
journal = "The African journal of medical sciences",
issn = "1116-4077",
publisher = "University College Hospital",
number = "4",

}

TY - JOUR

T1 - Awareness of anti-malarial policy and malaria treatment practices of patent medicine vendors in three Nigerian states.

AU - Oladepo, O.

AU - Brieger, William R

AU - Adeoye, B.

AU - Lawal, B.

AU - Peters, David

PY - 2011/12

Y1 - 2011/12

N2 - This paper assesses Patent Medicine Vendors' (PMVs) practices, awareness of new Nigerian Artemisinin Combination Therapy (ACT) policy, the anti-malarial drugs in stock and how the PMVs identify fake drugs. PMVs and medicine shops were selected through a multi-stage random sampling process, beginning with the purposive selection of three states that reflect major geographic and ethnolinguistic areas of Nigeria: Oyo (Southwest-Yoruba), Kaduna (Northcentral-Hausa), and Enugu (Southeast-Igbo). Local Government Areas (LGAs) in selected states were stratified into urban and rural strata, with two LGAs randomly sampled from each stratum in each state, and one ward (urban LGAs) or community (rural LGAs) randomly sampled from a list in each LGA. A complete listing of PMVs and drug shops was constructed at each site, yielding 111 PMVs and 106 medicine shops. Out of this number, a total of 110 PMVs consented to be interviewed. Some PMVs (43.1%) were aware of the 2005 government policy that changed the recommended first-line treatment for malaria from chloroquine (CQ) to ACT, but significant differences were found between states (p <0.001). PMV shops stocked many brands of anti-malarial drugs (average 5.5 brands), with ACTs stocked in only 8.5% of the stores at a mean price of N504 ($4) per treatment, compared to sulfadoxine-pyrimethamine (92% of shops, mean price of N90 ($0.7) and even monotherapy artesunates (32% of shops, mean price of N39 ($0.3). The PMVs identify a drug not bearing the National Agency for Food & Drug Administration and Control (NAFDAC) identification number as being fake or counterfeit. PMVs need to be a part of the strategy to change treatment to ACTs if there are to be meaningful changes in the anti-malarial drugs that Nigerians receive.

AB - This paper assesses Patent Medicine Vendors' (PMVs) practices, awareness of new Nigerian Artemisinin Combination Therapy (ACT) policy, the anti-malarial drugs in stock and how the PMVs identify fake drugs. PMVs and medicine shops were selected through a multi-stage random sampling process, beginning with the purposive selection of three states that reflect major geographic and ethnolinguistic areas of Nigeria: Oyo (Southwest-Yoruba), Kaduna (Northcentral-Hausa), and Enugu (Southeast-Igbo). Local Government Areas (LGAs) in selected states were stratified into urban and rural strata, with two LGAs randomly sampled from each stratum in each state, and one ward (urban LGAs) or community (rural LGAs) randomly sampled from a list in each LGA. A complete listing of PMVs and drug shops was constructed at each site, yielding 111 PMVs and 106 medicine shops. Out of this number, a total of 110 PMVs consented to be interviewed. Some PMVs (43.1%) were aware of the 2005 government policy that changed the recommended first-line treatment for malaria from chloroquine (CQ) to ACT, but significant differences were found between states (p <0.001). PMV shops stocked many brands of anti-malarial drugs (average 5.5 brands), with ACTs stocked in only 8.5% of the stores at a mean price of N504 ($4) per treatment, compared to sulfadoxine-pyrimethamine (92% of shops, mean price of N90 ($0.7) and even monotherapy artesunates (32% of shops, mean price of N39 ($0.3). The PMVs identify a drug not bearing the National Agency for Food & Drug Administration and Control (NAFDAC) identification number as being fake or counterfeit. PMVs need to be a part of the strategy to change treatment to ACTs if there are to be meaningful changes in the anti-malarial drugs that Nigerians receive.

UR - http://www.scopus.com/inward/record.url?scp=84864839812&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864839812&partnerID=8YFLogxK

M3 - Article

C2 - 22783684

AN - SCOPUS:84864839812

VL - 40

SP - 345

EP - 352

JO - The African journal of medical sciences

JF - The African journal of medical sciences

SN - 1116-4077

IS - 4

ER -